ClinicalTrials.gg
TerminatedNCT03621436TRVDUpdated Aug 15, 2019

Clinical Evaluation of the TRVD™ System in ADHF

An interventional study of TRVD Therapy in Acute Heart Failure, Congestive Heart Failure and Heart Failure, Congestive, sponsored by Magenta Medical Ltd.. Terminated at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-15.

Sponsored by Magenta Medical Ltd. · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
Study was terminated due to sponsor decision

From the registry’s dates

  • Registered 2 years 10 months after the study started (first participant enrolled Aug 2015, registered Jun 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 197 studies in Heart Failure with a site in Belgium — 27 open to participants now, 45 under way, 8 of them phase 3. Heart Failure · Belgium.

Enrollment
146th of 155
13 · median 262
Started
2015
with 4 others
No phase
78 of 197
13 open now
Registered
124th of 197
by date

Among the 197 studies in Heart Failure with a site in Belgium, this one is the 146th largest by enrollment of the 155 interventional ones that give a count, is one of 5 that started in 2015, is one of 78 with no phase, and was the 124th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

27 of the 197 studies in Heart Failure with a site in Belgium are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 197 studies in Heart Failure with a site in Belgium, or all of them as a file.
02

Study summary

A prospective, multi-national, open-label clinical study which is conducted to asses the safety, feasibility and performance of the TRVD™ System in hospital-admitted patients with Acute Decompensated Heart Failure (ADHF) and evidence of reduced left ventricular ejection fraction.

The study will include patients who present with significant venous congestion, as evidenced by clinical, laboratory and imaging signs of fluid retention.

Study participation, for each enrolled subject, will last approximately 3 months post index procedure.

Patients will be evaluated from enrollment until hospital discharge, then at 30, 60, and 90 days post procedure.

03

Conditions studied

  • Acute Heart Failure
  • Congestive Heart Failure
  • Heart Failure, Congestive

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient is 18 years of age or older
  2. Patient admitted to the hospital with a primary diagnosis of ADHF who is chronically treated with at least one oral loop diuretic.
  3. Patient presents at least two of the following clinical signs of manifest volume overload: 3.1 Jugular venous distension 3.2 Dyspnea, rales, or evidence of pulmonary congestion or oedema on admission chest radiography 3.3 Abdominal discomfort compatible with internal organ congestion and/or hepatomegaly 3.4 Peripheral oedema
  4. Ultrasonic evidence of IVC plethora, defined as IVC diameter >2.0 cm.
  5. BNP levels >300 pg/dL or NT-proBNP >1500 pg/dL .
  6. Evidence of cardiac etiology as per cardiac ultrasonography.
  7. =/\<40%.
  8. CVP (Invasively measured) >/=14 mmHg
  9. Male or non-pregnant / non-lactating female (NOTE: Females of child bearing potential must have a negative pregnancy test).
  10. Patient understands the nature of the procedure and provides written prior to any study specific assessments.

Exclusion criteria

Exclusion Criteria:

  1. >3, use of a NOAC in the past 48 hours or to systemic anticoagulation with Heparin.
  2. Evidence of hemodynamic instability, evidence of shock with organ hypoperfusion, or need for inotropic support.
  3. Overt pulmonary oedema, or Respiratory insufficiency/hypoxia (peripheral saturation \<90% with supplemental oxygen), need for non-invasive positive pressure ventilation or intubation.
  4. Severe renal dysfunction ( before decompensation \<45 ml/min/1.73 m2 BSA or \<25 on admission).
  5. Known renal artery stenosis.
  6. Known intrinsic kidney disease (e.g., established diagnosis of diabetic nephropathy with macroproteinuria, chronic glomerulonephritis).
  7. Severe anaemia (haemoglobin \<9 mg/dL).
  8. Thrombocytopenia with a count \<100,000.
  9. Acute coronary syndrome within 4 weeks prior to admission.
  10. Active myocarditis or hypertrophic obstructive cardiomyopathy.
  11. Complex congenital heart disease.
  12. Severe valvular stenosis.
  13. Severe morbid obesity ( >35).
  14. Fluid retention that is not primarily of cardiac origin (e.g., advanced liver disease, severe hypo-albuminaemia, etc.)
  15. Temperature > 38°C (oral or equivalent), or sepsis, or active systemic infection requiring IV anti-microbial treatment.
  16. Large ascites per ultrasound/CT.
  17. Cognitive impairment.
  18. Planned PCI, or more than minor surgery in the next 3 months.
  19. Moribund patient, or patient with or other comorbidities limiting to less than one year.
  20. Patient has a known allergy to Nickel.
  21. Contraindication to recommended study medications or intravascular contrast material that cannot be adequately controlled with pre-medication.
  22. Concurrent enrollment in another device or drug trial that has not completed the primary endpoint or clinically interferes with the current study endpoints.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    TRVD Therapy

    Device: TRVD Therapy

Interventions

  • DeviceTRVD Therapy

    A catheter-mounted expandable flow pump is to be deployed in a transfemoral venous catheterization procedure. Once in place, renal venous pressure is reduced to a pre-selected physiologic target pressure and kept there for up to 24 hours. After termination of TRVD therapy, the device is removed.

06

What researchers measure

Primary outcomes

  1. Preliminary Safety (device- and procedure-related SAEs)

    Incidence of device- and procedure-related SAEs

    Time frame: 30 days post index procedure

  2. Feasibility (technical success)

    Rate of technical success (defined as successful delivery and deployment, adequate function during device operation and successful retrieval) at hospital discharge.

    Time frame: Hospital discharge (at least 96 hours following index procedure)

  3. Feasibility (procedural success)

    Rate of procedural success (defined as absence of device-related SAEs) at hospital discharge.

    Time frame: Hospital discharge (at least 96 hours following index procedure)

Secondary outcomes

  1. Initial performance (effectiveness of renal venous pressure reduction)

    Invasively assessed renal venous pressure reduction from baseline (in mmHg)

    Time frame: Up to 24 hours

07

Study locations

3 sites
  • OLV-Hospital Aalst, Belgium
    Aalst, 9300, Belgium
  • Clinical Hospital Centre Zagreb
    Zagreb, 10000, Croatia
  • Zemun Clinical Hospital Center
    Belgrade, Serbia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2015 to primary completion in Apr 2019, 44 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2018
First posted
Aug 8, 2018
StartActual
Aug 7, 2015
Primary completionActual
Apr 2019
CompletionActual
May 2019
Last update
Aug 15, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03621436
Lead sponsor
Magenta Medical Ltd.
Responsible party
Sponsor
First posted
Aug 8, 2018
Start date
Aug 7, 2015
Primary completion
Apr 2019
Completion
May 2019
Last update
Aug 15, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion